The global HIV community had been waiting months for updated figures from PEPFAR — the U.S. President’s Emergency Plan for AIDS Relief, which began in 2003 and receives about $5 billion a year. After a freeze on foreign aid early in 2025, quarterly public reporting paused for months. When a new dataset was posted one spring Friday, reactions split sharply between administration officials who emphasized resilience and outside experts who warned of serious damage.
The State Department and other administration voices stressed continuity. They noted that, as of the end of September 2025, the U.S. supported HIV treatment for over 20 million people across 50 countries, a decline described as modest from the prior year. Officials highlighted protected priorities such as programs to prevent mother-to-child transmission and pointed to a substantial rise in a specific prevention measure: new starts of PrEP among pregnant and breastfeeding women increased from roughly 43,000 in the final quarter of 2024 to about 103,000 in the same quarter of 2025. Acting undersecretary Jeremy Lewin and others framed the numbers as evidence that core global health activities remained intact despite recent turmoil.
Activists, researchers and many technical experts drew a different conclusion. Groups including Health GAP and AmfAR, along with specialists from the International AIDS Society, described the data as showing widespread disruptions in testing, prevention and support services. Critics said the headline treatment totals hide declines in the systems that find and retain people in care. AmfAR’s deputy director of public policy, Brian Honermann, argued that the administration’s presentation understates the harms caused by the 2025 interruptions.
PEPFAR has been known for regular, detailed public reporting that allowed program managers, advocates and analysts to track outcomes and hold implementers accountable. That transparency made it possible to see where interventions were working and where gaps were emerging; many of PEPFAR’s indicators were set deliberately high to ensure accountability.
The new release shows changes that experts tie to altered funding decisions and program structures after the aid freeze. External analyses and PEPFAR observers point to a large reduction in frontline staff: roughly 24% of workers supported by the program were no longer in place, many laid off when activities judged not immediately life-saving were paused. Those positions included community health workers who conduct home visits and facilitators who run peer-support groups for adolescents — roles that are central to prevention, case-finding and retention in care.
The staffing and service shifts correlate with declines in new diagnoses where services were disrupted. In facilities where programs were largely maintained, new HIV diagnoses fell by about 13%; in sites that experienced interruptions, diagnoses dropped nearly 30%. Experts warned that means hundreds of thousands who would have been identified and started on treatment are missing from care, which harms patients and raises the risk of onward transmission at the population level.
In response to these critiques, the State Department framed its approach as a deliberate prioritization of limited resources: officials said overall spending was cut by about 30% while essential frontline HIV care was preserved and “inefficient” or lower-priority activities were ended, presenting that approach as consistent with the America First Global Health Strategy.
The disagreement reflects a broader tension about how to interpret program performance during shocks. Administration accounts point to aggregate treatment totals and selected prevention gains as proof that core services survived. Many activists and technical experts counter that headline figures can mask disruptions in the outreach, testing and peer-support systems that sustain long-term gains. Where community-based work and case-finding are weakened, treatment numbers may appear stable only until untested or unsupported people fall out of care.
Researchers are rapidly unpacking the new dataset, and their analyses are likely to influence policy and funding choices in the year ahead. For now, the release offers both reasons for cautious optimism — that millions remain on treatment and some prioritized interventions expanded — and clear warnings about the vulnerability of HIV programs to policy and funding shocks. It also shows how a single set of numbers can be read in very different ways depending on what metrics and timeframes observers emphasize.